公开(公告)号：US11931406B2

公开(公告)日：2024-03-19

申请号：US16772131

申请日：2018-12-12

申请人： CureVac SE ,  Sanofi Pasteur

发明人： Patrick Baumhof ,  Wolfgang Grosse ,  Edith Jasny ,  Thomas Kramps ,  Daniel Voss ,  Julia Dannenmaier ,  Valérie Lecouturier ,  Yves Girerd-Chambaz

IPC分类号： A61K39/12 ,  A61P31/14 ,  A61K39/00

CPC分类号： A61K39/12 ,  A61P31/14 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/6031 ,  C12N2770/24134

摘要： The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.

公开(公告)号：US11739125B2

公开(公告)日：2023-08-29

申请号：US17316834

申请日：2021-05-11

申请人： CureVac SE

发明人： Thomas Kramps ,  Margit Schnee ,  Daniel Voss ,  Benjamin Petsch

IPC分类号： C07K14/005 ,  A61K39/12 ,  C12N7/00 ,  A61K39/155 ,  C07K16/10 ,  A61K39/00 ,  A61K48/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  C07K16/1027 ,  C12N7/00 ,  A61K48/00 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/6031 ,  C07K2317/24 ,  C12N2760/18534

摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

公开(公告)号：US11965000B2

公开(公告)日：2024-04-23

申请号：US18463276

申请日：2023-09-07

申请人： CureVac SE

发明人： Thomas Kramps ,  Margit Schnee ,  Daniel Voss ,  Benjamin Petsch

IPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  C07K16/10 ,  C12N7/00 ,  A61K39/00 ,  A61K48/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  C07K16/1027 ,  C12N7/00 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/6031 ,  A61K48/00 ,  C07K2317/24 ,  C12N2760/18534

摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.